Multiple sclerosis (MS) most commonly presents in young adults, although 3–5% of patients
develop MS prior to the age of 18 years. The new and comprehensive consensus for the …

For the past 10 years, disease-modifying therapy (DMT) options for multiple sclerosis (MS)
have grown remarkably where DMTs have been shown to reduce the risk of MS relapses. MS …

Objectives: To assess the impact of a stroke code on the door to needle time during Hajj at a
tertiary center in Makkah, Saudi Arabia. Stroke is one of the most common medical …

This article deals with recommendations on the management of symptoms of MS and on the
provision of vaccinations in patients receiving disease-modifying therapies (DMTs). …

Objectives: To assess the efficacy and safety of rituximab for multiple sclerosis (MS) treatment
in terms of reduction in clinical relapses, magnetic resonance imaging (MRI) activity, …

Introduction: While accreditation is thought to promote healthcare quality, a literature review
revealed a scarcity of studies conducted in Saudi Arabia addressing the relationship …

Glue sniffing neuropathy commonly known as n-hexane neuropathy. It is well documented
that industrial exposure to n-hexane causes neuropathy, however it is less well recognized …

Glue sniffing neuropathy commonly known as n-hexane neuropathy. It is well documented
that industrial exposure to n-hexane causes neuropathy, however it is less well recognized …

Introduction: While accreditation is thought to promote healthcare quality, a literature review
revealed a scarcity of studies conducted in Saudi Arabia addressing the relationship …

Background: Stroke and systemic embolic occurrences have been significantly reduced by
novel oral anticoagulants, though theoretically a side effect of this anticoagulant treatment is …